PIXXGEN
PIUR IMAGING Deutschland
PIUR IMAGING, a medtech innovator transforming diagnostic ultrasound imaging through AI-driven tomographic ultrasound solutions. Our vision is to make high-quality healthcare accessible and affordable everywhere. By combining advanced imaging technology with intelligent software, PIUR IMAGING enables faster diagnostics, more consistent results, and streamlined clinical workflows.
Philips
Philips is a leading health technology company focused on improving people’s lives – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that help provide improved patient experience, better health outcomes, improved staff experience, and lower cost of care. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. | Designed for ease of use, Philips automated external defibrillators (AEDs) are ready to act when you are. They provide treatment of the most common cause of sudden cardiac arrest (SCA) by delivering a shock quickly and effectively, wherever SCA happens. HeartStart AEDs guide you through the rescue process, including CPR and how to initiate an electrical current if recommended. Our AED devices are designed for every use type, whether inside or outside, in varying environments or at home, so you can help save a life anytime, anywhere. Supplies and our AED accessories are available online, so replenishing your AED supplies and accessories, such as batteries and electrode pads, are a few clicks away. | At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better. | Philips is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. | Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
PhenX Toolkit
The PhenX (consensus measures for Phenotypes and eXposures) Toolkit is a web-based catalog of recommended measurement protocols of phenotypes and exposures suitable for inclusion in genomic, clinical, and translational research studies with human participants.
PHC Corporation of North America
PHC Corporation of North America located in Wood Dale, IL, is a leader in laboratory equipment for the biopharmaceutical, life sciences, academic, healthcare and government markets. Product lines under the PHCbi brand include the space saving and energy efficient VIP® ECO and TwinGuard® ultra-low temperature freezers, cryogenic and biomedical freezers, pharmacy and high-performance refrigerators, cell culture CO2 and multigas incubators, Drosophila/plant growth chambers, and cell and gene therapy solutions. PHC Corporation of North America is a subsidiary of PHC Holdings Corporation, Tokyo, Japan, which is a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, diagnostics and life sciences. | PHC Corporation of North America (PHCNA), headquartered in Wood Dale, IL, is a supplier of PHCbi life sciences laboratory solutions. PHCNA empowers scientific advancement by providing technologies that protect and support critical research. PHCbi solutions provided by PHCNA are trusted by researchers across the United States, Canada, and select countries in Latin America for their reliability and innovation. PHCbi is a global leader in life science laboratory equipment, offering solutions that enhance every stage of the research workflow—from sample preservation to cell culture to regenerative medicine. PHCNA is a proud subsidiary of PHC Holdings Corporation (TSE 6523), based in Tokyo, Japan — a global healthcare enterprise that develops, manufactures, distributes, and services solutions across diabetes management, healthcare solutions, diagnostics and life sciences. | PHC Corporation of North America (PHCNA) is headquartered in Wood Dale, IL and manufactures and markets PHCbi brand laboratory equipment. PHCNA is a subsidiary of PHC Holdings Corporation of Tokyo, Japan, a global diversified diagnostics, life sciences, and medical device company. Our goal is to support the work of our customers and to improve the health and well-being of people around the world. For more than 50 years, PHCNA has met the needs of pharmaceutical, biotechnology, hospital/clinical and industrial customers, offering a unique perspective on scientific research. We play a critical role in global product development for a wide variety of applications and have established a reputation as a manufacturer of high-quality and innovative medical, diagnostic, and laboratory equipment. Our products are marketed as the PHCbi brand, and our product lines include CO2 and multigas incubators, ultra-low temperature freezers, cryogenic and biomedical freezers, and high-performance refrigerators | PHC Corporation of North America, located in Wood Dale, IL, is a leader in laboratory equipment for the biopharmaceutical, life sciences, academic, healthcare and government markets. Product lines under the PHCbi brand include the space saving and energy efficient VIP® ECO and TwinGuard® ultra-low temperature freezers, cryogenic and biomedical freezers, pharmacy and high-performance refrigerators, cell culture CO2 and multigas incubators, and Drosophila/plant growth chambers. PHC Corporation of North America is a subsidiary of PHC Holdings Corporation, Tokyo, Japan, which is a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, diagnostics and life sciences.
Phase Clinical Services
Your complete resource for oncology clinical trials and biospecimens | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies. Our clients are pharma and biotech companies from startup to the top-ten level, assay developers, high-end academic institutions, and the U.S. government. We maintain an FDA-registered cell isolation lab in Milwaukee and an in-house pathology service. | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies.
PharSafer
Founded in 2003 by Dr Graeme Ladds, PharSafer® is a specialist Contract Research Organisation (CRO) in Global Clinical and Post Marketing Drug Safety, and Medical Services, with a wealth of experience in Pharmacovigilance, Auditing and Medical Affairs – and the various, numerous and extensive legal safety/medical obligations for licence holders to comply with – as well as Regulatory Strategy for the best methods for obtaining scientific advice concerning licence submissions and approvals. Together with our sister company which focuses on Training: SaPhar, PharSafer® continuously seeks new and innovative ways to provide added value for our global clients – going above and beyond expectations and optimising processes and procedures involved with clinical and post marketing drug safety and licencing approach. Our ability to offer first-class services in Pharmacovigilance, Regulatory Affairs, Training, Auditing, Medical Affairs and IT Informatics means that, for many clients, we operate as their Pharmacovigilance and Medical Departments – guiding them through the labyrinth of drug safety and medical legislation, all in the interests of ensuring patient safety and client compliance. We love what we do. We love finding solutions. Quite simply, we are by far… Your leading partner in Drug Safety. | PharSafer is a Global CRO specialising in Clinical & Post Marketing Pharmacovigilance; Medical Affairs; Training; Auditing; IT Informatics and Regulatory Intelligence. PharSafer have been operating for the last 23 years growing annually and helping take Companies from their clinical to post-marketing phases and many clients have been with us over 10 years now. PharSafer have attended over 100 inspections on behalf of clients to aid their compliance and ensure Regulatory Authorities are satisfied with the activities being performed. PharSafer are also an innovative Company designing validated and automated systems to provide cost-effective solutions for clients and ensure Regulatory compliant systems. Our client base is truly global being in all continents and for clients that have drugs; devices; vaccines; biologics; advanced therapies; biosimilars; herbal and cosmetics. Our Team within the Company are very experienced (many with over 15 years experience) aided by our sister training Company (SaPhar) to provide new updates for clients on country specific regulations with regular monthly contacts and comments going to all clients. We would be happy to engage with you and talk about product development; product expansions into new countries; product launches and perform all of the activities mentioned above. Please review of website and we look forward to engaging with you personally.
Pharmtrace Klinische Entwicklung GmbH
pharmtrace is an independent CRO providing strategies and solutions for clinical trials. pharmtrace offers flexible services and a global reach for studies with imaging endpoints, radiopharmaceuticals, and radiological interventional procedures. pharmtrace’s experienced team and international medical specialists network ensure that your investment in medical imaging, radiopharmaceuticals and radiological interventions delivers meaningful data. With our GCP compliant image management platform (ERICA) we support you to generate robust data to convince authorities and decision makers, and to achieve your development target. pharmtrace’s customers include biotech and academia, as well as internationally engaged pharmaceutical companies and device manufacturers. | Full-service clinical trial management by a team that understands imaging and radiopharmaceuticals as deeply as clinical operations. pharmtrace is a private, independent contract research organisation for the pharmaceutical and medical device industry. We focus on clinical studies where diagnostic imaging and/or nuclear medicine approaches are a major component for efficacy or safety assessment — including RECIST-based oncology trials, therapeutic radiopharmaceutical programmes, and medical device investigations. Our clients are global pharmaceutical companies, biotech firms, and academic sponsors across North America, Europe, and Australasia. We have managed clinical trials across oncology, neurology, cardiology, and other therapeutic areas — from first-in-human exploratory studies through Phase 3 registration trials and Phase 4 post-marketing commitments. In each, imaging expertise was built in from the protocol stage, not retrofitted. Our experience includes studies that have supported marketing authorisation applications to FDA and EMA. We know what these submissions require and design our processes accordingly from the outset. pharmtrace’s Imaging Core Lab provides comprehensive support for all imaging aspects of clinical trials and medical device investigations. Whether your study applies RECIST 1.1 or iRECIST for tumour response in oncology, PERCIST for PET-based assessment, quantitative MRI endpoints in neurology, SPECT imaging in cardiology, or quantitative imaging for a medical device investigation — we standardise, collect, quality-control, and independently review images with the rigour that regulatory submissions require. Our proprietary ERICA platform, validated to GAMP5 Category 5, serves as the single environment for DICOM image storage, technical and medical QC, and blinded read sessions — with per-study configuration validation for every project. We support sponsors at any stage — from early imaging strategy and endpoint selection through regulatory meeting preparation and marketing authorisation support. Our advice is grounded in operational experience, not theory.
Pharmigene Inc
Established in 2005, Pharmigene Inc. is a leading biotechnology company specializing in pharmacogenomic testing. We hold exclusive global licenses from Academia Sinica for patents related to genetic testing for Warfarin and other critical medications such as Carbamazepine and Allopurinol. Leveraging these proprietary technologies, we have developed advanced diagnostic products and tools that have secured comprehensive technical patent certifications across numerous countries worldwide, including the USA, Europe, New Zealand, Australia, Japan, China, India, and Southeast Asia.Headquartered in Taiwan, Pharmigene operates a state-of-the-art R&D center and maintains stringent quality management systems. Our commitment to excellence is underscored by our certifications, including international ISO 13485, Taiwan QMS (GMP), and South Korea KGMP, ensuring the highest standards in medical device manufacturing and diagnostic solutions.
PharmaResources(Shanghai) Co., Ltd.
PharmaResources, established in 2007, is a comprehensive one-stop service provider for new drug R&D as well as commercial production. We are dedicated to the drug discovery, pharmaceutical processes R&D, and the commercial manufacturing of APIs and intermediates | PharmaResources, established in 2007, is a comprehensive one-stop service provider for new drug R&D as well as commercial production. We are dedicated to the drug discovery, pharmaceutical processes R&D, and the commercial manufacturing of APIs and intermediates. Our new drug R&D services cover the entire process of preclinical new drug research, primarily including drug discovery and processR&D. In drug discovery, we assist clients in designing, screening, and optimizing hit compounds and lead compounds , conducting structural improvements, and preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights.In our process R&D servicewe provide new drug process chemistry services and innovative synthetic process development for global pharmaceutical companies,helping clients to achieve cost-effective, safe, green, and reliable commercial manufacturing of intermediates and APIs in scales from kilograms to tons. Leveraging our technological advantages in pharmaceutical process technology, we also engage in the customized manufacturing services of key drug intermediates,as well as independent research and development and manufacturing of specialty APIs intermediates with complex chemical structures and high synthesis difficulties. In March 2021, PharmaResources’ IPO application for GEM was accepted by the Shenzhen Stock Exchange. In April 2022, it successfully passed the review of the Listing Committee of the Shenzhen Stock Exchange.On July 8, 2022, the China Securities Regulatory Commission approved the application of PharmaResources (Shanghai) Co.,Ltd. for an initial public offering of stocks and listing on the Shenzhen GEM. On October 18, 2022, PharmaResources issued 19.25 million A-shares in its initial public offering and was listed on the GEM. As advocated in the core values of PharmaResources, ‘Science-driven, continuous innovation’.Regardless of how the internal and external environment may change, ‘Science and Innovation’ is the perpetual goals of our team. Only by consistently pursuing scientific excellence and technological innovation can we meet the ever-changing needs of our clients and the market, while ensuring the sustainable competitiveness of our company.